CONTACTS: For Genzyme Sally Curley (investors) (617) 591-7140 Dan Quinn (media) (617) 591-5849 For MacroGenics Michael Richman (301) 354-0681 For Immediate Release October 29, 2003 CAMBRIDGE, Mass. and Rockville, Md . Genzyme Corp. (Nasdaq: GENZ) and MacroGenics, Inc.
HHS Names UTMB, Seven Others as New Regional Centers To Focus on Biodefense Research The Department of Health and Human Services (HHS) today announced that the University of Texas Medical Branch at Galveston (UTMB) is among eight institutions nationwide receiving grants totaling approximately $350
MacroGenics Announces Senior Appointments Rockville, MD April 1, 2002 - MacroGenics, Inc., a biotechnology company that is developing immunotherapeutics for treating cancer and inflammatory diseases, announced two key appointments to the senior management team. Michael S.
Former MedImmune Senior Vice President joins MacroGenics; Company completes key license agreements and closure of second tranche of Series A financing, bringing total raised to $13.5MM.
